Antithyroid medications and psychosis

Expert Opinion on Drug Safety

Volumn 12, Issue 6, 2013, Pages 865-872

  Vita, Roberto ^a   Mazzi, Valeria ^b   Antonelli, Alessandro ^b   Benvenga, Salvatore ^a,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Acute psychosis; Antithyroid drugs; Graves' disease; Hyperthyroidism

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; LIOTHYRONINE; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; PROPYLTHIOURACIL; THIAMAZOLE; THIOURACIL; THYROID HORMONE; THYROTROPIN; THYROXINE;

ACCURACY; ACUTE PSYCHOSIS; AGRANULOCYTOSIS; ARTHRALGIA; AUTOIMMUNE THYROIDITIS; CHOLESTASIS; DELIRIUM; DRUG SAFETY; DRUG WITHDRAWAL; EUTHYROIDISM; GRANULOCYTOPENIA; HALLUCINATION; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOPROTHROMBINEMIA; HYPOTHYROIDISM; LUPUS ERYTHEMATOSUS; NONHUMAN; PANCREATITIS; POLYARTHRITIS; RADIOIMMUNOASSAY; RASH; REVIEW; THYROID HORMONE BLOOD LEVEL; URTICARIA; VASCULITIS;

ANIMALS; ANTITHYROID AGENTS; DRUG MONITORING; HUMANS; HYPERTHYROIDISM; MENTAL DISORDERS; PSYCHOSES, SUBSTANCE-INDUCED; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 84886616327     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.823397     Document Type: Review

References (67)

1. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-17
2. Nakashima T, Taurog A. Rapid conversion of carbimazole to methimazole in serum; evidence for an enzymatic mechanism. Clin Endocrinol (Oxf) 1979;10:637-48
3. Wolff J. Perchlorate and the thyroid gland. Pharmacol Rev 1998;50:89-105
4. Nygaard B. Hyperthyroidism (primary). Clin Evid (Online) 2008;2008:0611
5. Heinrich TW, Grahm G. Hypothyroidism presenting as psychosis: Myxedema madness revisited. Prim Care Companion J Clin Psychiatry 2003;5:260-6
6. Bauer M, Samuels MH, Whybrow PC. Behavioral and psychiatric aspects of thyrotoxicosis. In: Braverman LE, Cooper D, editors. Werner & Ingbar's the thyroid: A fundamental and clinical textbook. Lippincott, Williams & Wilkins; Philadelphia, Pennsylvania: 2000. p. 673-8
7. Herridge CF, Abey-Wickrama I. Acute iatrogenic hypothyroid psychosis. Br Med J 1969;3:154
8. Benvenga S, Lapa D, Trimarchi F. Don't forget the thyroid in the etiology of psychoses. Am J Med 2003;115:159-60
9. Jansson R, Lindstrom B, Dahlberg PA. Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 1985;10:443-50
10. Cooper DS, Steigerwalt S, Migdal S. Pharmacology of propylthiouracil in thyrotoxicosis and chronic renal failure. Arch Intern Med 1987;147:785-6
11. Glatstein MM, Garcia-Bournissen F, Giglio N, et al. Pharmacologic treatment of hyperthyroidism during lactation. Can Fam Physician 2009;55:797-8
12. Okamura K, Ikenoue H, Shiroozu A, et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1987;65:719-23
13. Moriyama K, Tagami T, Usui T, et al. Antithyroid drugs inhibit thyroid hormone receptor-mediated transcription. J Clin Endocrinol Metab 2007;92:1066-72
14. Davidson B, Soodak M, Neary JT, et al. The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil in vitro and its relationship to in vivo findings. Endocrinology 1978;103:871-82
15. Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: A review. Curr Pharm Des 2001;7:451-60
16. Bandyopadhyay U, Biswas K, Banerjee RK. Extrathyroidal actions of antithyroid thionamides. Toxicol Lett 2002;128:117-27
17. Totterman TH, Karlsson FA, Bengtsson M, et al. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med 1987;316:15-22
18. Zantut-Wittmann DE, Tambascia MA, da Silva Trevisan MA, et al. Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves' disease. Thyroid 2001;11:575-80
19. Salvi M, Girasole G, Pedrazzoni M, et al. Increased serum concentrations of interleu- kin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 1996;81:2976-9
20. Sonnet E, Massart C, Gibassier J, et al. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J Endocrinol Invest 1999;22:430-5
21. Antonelli A, Fallahi P, Rotondi M, et al. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006;93:1226-31
22. Antonelli A, Rotondi M, Fallahi P, et al. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006;64:189-95
23. Antonelli A, Ferrari SM, Fallahi P, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: Modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009;94:1803-9
24. Antonelli A, Ferrari SM, Frascerra S, et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 2010;95:E413-20
25. Antonelli A, Ferrari SM, Frascerra S, et al. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 2011;96:1859-63
26. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593-646
27. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 1995;273:808-12
28. Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7:369-75
29. Cooper DS. The side effects of antithyroid drugs. Endocrinologist 1999;9:457-76
30. Toth EL, Mant MJ, Shivji S, et al. Propylthiouracil-induced agranulocytosis: An unusual presentation and a possible mechanism. Am J Med 1988;85:725-7
31. Julia A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: Prognostic factors in a series of 168 episodes. Br J Haematol 1991;79:366-71
32. Wing SS, Fantus IG. Adverse immunologic effects of antithyroid drugs. CMAJ 1987;136:121-7
33. Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995;80:1083-5
34. Liaw Y-F, Huang M-J, Fan K-D, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. Ann Intern Med 1993;118:424-8
35. Gunton JE, Stiel J, Caterson RJ. Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis: A case report and review of the literature. J Clin Endocrinol Metab 1999;84:13-16
36. Horton RC, Sheppard MC, Emery P. Propylthiouracil-induced systemic lupus erythematosus. Lancet 1989;2:568
37. Uchigata Y, Eguchi Y, Takayama-Hasumi S, et al. Insulin autoimmune syndrome (Hirata disease): Clinical features and epidemiology in Japan. Diabetes Res Clin Pract 1994;22:89-94
38. Lipsky JJ, Gallego MO. Mechanism of thioamide antithyroid drug associated hypoprothrombinemia. Drug Metabol Drug Interact 1988;6:317-26
39. Yang M, Qu H, Deng HC. Acute pancreatitis induced by methimazole in a patient with Graves' disease. Thyroid 2012;22:94-6
40. Chatagnon P. Les psychoses thyroidiennes dites endocriniennes et leur traitment chirurgical. Presse Me'd 1942;50:536
41. Brewer C. Psychosis due to acute hypothyroidism during the administration of carbimazole. Br J Psychiatry 1969;115:1181-3
42. Witton K. Acute transitory psychotic reaction manifested after radio-iodine treatment for hyperthyroidism. Am J Psychiatry 1959;1:746-7
43. Williams RH, Clute HW, Anglem TJ, et al. Thiouracil treatment of thyrotoxicosis; toxic reactions. J Clin Endocrinol Metab 1946;6:23-51
44. Kammerer TH, Singer L, Wackenheim A. Troubles mentaux après thyroidectomie. C.R. 52- session Congrès Med. Alie'n. et Neurol. de langue française. Masson èdit.; Paris; 1954. p. 324 (See ref. 54
45. Burch HB, Wartosfky L. Life-threatening hyperthyroidism: Thyroid storm. Endocrinol Metab Clin North Am 2003;22:263-77
46. Khemka D, Ali JA, Koch CA. Primary hypothyroidism associated with acute mania: Case series and literature review. Exp Clin Endocrinol Diabetes 2011;119:513-17
47. Whybrow PC. Iatrogenic hypothyroid psychosis. Br Med J 1969;3:474-5
48. Hashizume Y, Yamaki T, Hidaka H. Effect of anti-thyroid agents, methimazole and propylthiouracil, on brain noradrenaline content. Br J Pharmacol 1977;59:157-62
49. Rosenberg RC. Inhibition of dopamine beta-hydroxylase by 2-mercapto-1- methylimidazole. Biochim Biophys Acta 1983;749:276-80
50. Suzukawa K, Kondo K, Kanaya K, et al. Age-related changes of the regeneration mode in the mouse peripheral olfactory system following olfactotoxic drug methimazole-induced damage. J Comp Neurol 2011;519:2154-74
51. Xu W, Slotnick B. Olfaction and peripheral olfactory connections in methimazole-treated rats. Behav Brain Res 1999;102:41-50
52. Bergman U, Brittebo EB. Methimazole toxicity in rodents: Covalent binding in the olfactory mucosa and detection of glial fibrillary acidic protein in the olfactory bulb. Toxicol Appl Pharmacol 1999;155:190-200
53. Chiba K, Horii H, Kubota E, et al. Effects of N methylmercaptoimidazole on the disposition of MPTP and its metabolites in mice. Eur J Pharmacol 1990;180:59-67
54. Zerbi D. Contribution to the study of mental disorders in hyperthyroidism: Psychotic manifestations in the course of antithyroid therapy. Rass Studi Psichiatr 1964;53:579-90
55. Bowers M, Singer D. Thyrotoxicosis and the psychological state. Psychosomatics 1964;5:322-4
56. Bewsher PD, Gardiner AQ, Hedley AJ, et al. Psychosis after acute alteration of thyroid status. Psychol Med 1971;1:260-2
57. Jha S, Waghdhare S, Reddi R, et al. Thyroid storm due to inappropriate administration of a compounded thyroid hormone preparation successfully treated with plasmapheresis. Thyroid 2012;22:1283-6
58. Merikas G, Vervesos K, Marketos S. Reversible psychotic syndrome after potassium perchlorate treatment. Postgrad Med J 1963;39:153-5
59. Methimazole Related Psychotic Disorder Reports (From AERS Data). Available from: Http://www.druginformer.com/ search/side-effect-details/ tapazole/ psychotic%20disorder.html [Last accessed 20 March 2013]
60. Irwin R, Ellis PM, Delahunt J. Psychosis following acute alteration of thyroid status. Aust N Z J Psychiatry 1997;31:762-4
61. Cantón A, de Fàbregas O, Tintoré M, et al. Encephalopathy associated to autoimmune thyroid disease: A more appropriate term for an underestimated condition? J Neurol Sci 2000;176:65-9
62. Tousson E, Ibrahim W, Arafa N, et al. Monoamine concentrations changes in the PTU-induced hypothyroid rat brain and the ameliorating role of folic acid. Hum Exp Toxicol 2012;31:282-9
63. Crocker AD, Overstreet DH. Modification of the behavioural effects of haloperidol and of dopamine receptor regulation by altered thyroid status. Psychopharmacology (Berl ;82:102-6
64. Pacak K, Tjurmina O, Palkovits M, et al. Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: An in vivo microdialysis study. Neuroendocrinology 2002;76:148-57
65. Schatzberg AF, Rothschild AJ. The roles of glucocorticoid and dopaminergic systems in delusional (psychotic depression. Ann N Y Acad Sci 1988;537:462-71
66. Kennedy B, Strassman RJ, Ziegler MG, et al. Cardiovascular, catecholamine and psychological responses to TRH in four types of affective disorder patients. Horm Metab Res 1987;19:164-7
67. Tamagno G, Celik Y, Simó R, et al. Encephalopathy associated with autoimmune thyroid disease in patients with Graves' disease: Clinical manifestations, follow-up, and outcomes. BMC Neurol 2010;10:27